13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000310158
Total reported value
$526.4M
$526.4M
13 檔
39.2%
In Q2 2025, Merck & Co., Inc.'s U.S. equity holdings reached a combined market value of $526.4M, distributed across 13 disclosed stock positions.
During Q2 2025, Merck & Co., Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including PSNL, MRNA, KYMR) accounted for 39.2% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PSNL | Personalis Inc | Stock-Other | 42.73% | +10.15% | — | |
| 2 | MRNA | Moderna Inc | Stock-Healthcare | 29.54% | -2.85% | — | |
| 3 | KYMR | Kymera Therapeutics Inc | Stock-Other | 15.63% | -1.58% | — | |
| 4 | ✓ | Stock-Other | 5.42% | -6.28% | EXIT | ||
| 5 | ALEC | Alector Inc | Stock-Other | 2.30% | -0.83% | — | |
| 6 | EVAXUSD | Evaxion Biotech A/s | Stock-Other | 1.38% | -1.29% | EXIT | |
| 7 | STRO | Sutro Biopharma, Inc. | Stock-Other | 0.90% | -1.94% | EXIT | |
| 8 | ✓ | Lava Therapeutics NV | Stock-Other | 0.70% | — | — | |
| 9 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.61% | -0.19% | — | |
| 10 | ✓ | Xilio Therapeutics Inc | Stock-Other | 0.47% | — | — | |
| 11 | CARM | Carisma Therapeutics Inc | Stock-Other | 0.27% | -0.01% | EXIT | |
| 12 | NEUP | Neuphoria Therapeutics Inc | Stock-Other | 0.03% | — | — | |
| 13 | HURA | Tuhura Biosciences Inc | Stock-Other | 0.01% | — | — |
According to official SEC Form 13F filings, Merck & Co., Inc. reported a total U.S. public equity portfolio value of $526.4M across 13 disclosed positions in Q2 2025.
During Q2 2025, Merck & Co., Inc.'s top holdings by market value included PSNL (42.7%)、MRNA (29.5%)、KYMR (15.6%). The largest single position, PSNL, represented 42.7% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q2 2025, Merck & Co., Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.